Interpretable artificial intelligence based determination of glioma IDH mutation status directly from histology slides.

Neurooncol Adv

Department of Computer Science, Luddy School of Informatics, Computing, and Engineering, Indiana University, Indianapolis, Indiana, USA.

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Isocitrate dehydrogenase (IDH) mutation status is a diagnostic requirement for glioma with associated prognostic and therapeutic implications. Clinical routine visual assessment of tissue is insufficient to determine IDH status conclusively, mandating molecular workup that is unavailable everywhere.

Methods: We developed an interpretable Artificial Intelligence (AI)-based approach for determining IDH status directly from H&E-stained glioma slides. Our study is based on 2442 multi-institutional whole slide images (WSIs) from 3 independent retrospective glioma collections, following their reclassification according to the WHO 2021 criteria: (1) TCGA-GBM/TCGA-LGG (  = 1534,  = 799), (2) University of Pennsylvania Health System collection (UPHS,  =   = 114), and (3) EBRAINS (  =   = 794). Method development is based on TCGA, whereas UPHS and EBRAINS are independent hold-out datasets for model validation. Six pathology-specific foundation AI models and an ImageNet-pretrained AI model facilitate robust feature extraction. Features are aggregated into slide-level representations via an interpretable multiple-instance learning (MIL) mechanism to differentiate IDH-wildtype from IDH-mutant cases and generate attention heatmaps correlating with identifiable morphologic characteristics.

Results: Our approach yields AUC = 0.96 over a 10-fold cross-validation schema and generalizable performance on independent validation (AUC = 0.97, AUC = 0.95). Interpretability analysis reveals high attention regions in IDH-wildtype tumors exhibiting significant pleomorphism and microvascular proliferation, while IDH-mutant tumors show dense nodular cell concentrations, microcysts, and gemistocytic cells.

Conclusions: Accurate H&E-based determination of glioma IDH mutation status can expedite conclusive diagnosis and clinical decision-making and even facilitate it in underserved regions. Finally, interpretability analysis of distilled human-identifiable features can further improve our understanding of the disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290450PMC
http://dx.doi.org/10.1093/noajnl/vdaf140DOI Listing

Publication Analysis

Top Keywords

idh mutation
12
mutation status
12
interpretable artificial
8
artificial intelligence
8
determination glioma
8
glioma idh
8
status directly
8
idh status
8
interpretability analysis
8
glioma
5

Similar Publications

Background: The objective of this study is to investigate the predictive role of O6-methylguanine-DNA methyltransferase (MGMT) and isocitrate dehydrogenase (IDH) status on the efficacy of bevacizumab (BEV) in high-grade glioma (HGG), while excluding the interference of chemotherapy agents.

Methods: A retrospective, single-center analysis was conducted on 103 patients with HGG who received BEV treatment. The enrolled patients were grouped based on their different biomarker statuses.

View Article and Find Full Text PDF

Isocitrate dehydrogenase mutation and microenvironment in gliomas: do immunotherapy approaches matter?

Curr Opin Neurol

September 2025

Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ).

Purpose Of Review: Gliomas with mutations in the gene for isocitrate dehydrogenase (IDH) display a unique immune microenvironment that is distinct from IDH-wildtype gliomas. This unique immune microenvironment is shaped by 2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH. These features provide an opportunity to develop and test targeted immunotherapies for IDH-mutant gliomas.

View Article and Find Full Text PDF

Glioblastoma (GB), IDH-wildtype (IDH-wt), is the most prevalent primary malignant brain neoplasm in adults. Despite adjuvant therapy, the prognosis for these tumors remains dismal, with a median survival of around 15-18 months. Although rare, extracranial metastases from GB are reported with increasing frequency, likely due to advancements in follow-up, treatments, and improved patient survival.

View Article and Find Full Text PDF

On August 6, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to vorasidenib (VORANIGO, Servier Pharmaceuticals, LLC) for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or 2 (IDH1 or IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.

View Article and Find Full Text PDF

Background: Therapies for diffuse glioma induce DNA damage response (DDR), and strategies to exploit DDR defects are active areas of investigation. While global DNA methylation profiling effectively classifies gliomas into subtypes, the epigenetic and gene expression patterns of DDR genes, and their contribution to tumor classification and outcomes, have yet to be fully elucidated. Thus, dissecting the DDR epigenetics, gene expression, and single-cell heterogeneity may reveal key molecular characteristics, refine prognosis, and identify novel treatment strategies and resistance mechanisms.

View Article and Find Full Text PDF